Table 2.
Endpoints examined in randomized trials of mobile phone technology in cardiovascular disease.
| Author | Population | Primary endpoint | Primary result | Major secondary endpoints | ||||
|
|
|
|
|
Mortality | Hospitalization | Blood pressure | BMI | Medication adherence |
| Blasco 2012 [14] | IHDa | Cardiovascular risk | NSb | NRc | NR | NS | NS | NR |
| Chow 2015 [15] | IHD | Lipid profile | Pd | NR | NR | P | P | NR |
| Fang 2016 [16] | IHD | Medication adherence | P | NR | NR | NR | NR | P1e |
| Khonsari 2015 [17] | IHD | Medication adherence | P | NS | NS | NR | NR | P1 |
| Park 2015 [18] | IHD | Medication adherence | P | NR | NR | NR | NR | P1 |
| Quilici 2013 [19] | IHD | Medication adherence | P | NR | NR | NR | NR | P1 |
| Chen 2019 [20] | HFf | Mortality | NS | NS1g | P | NR | NR | P |
| Dendale 2012 [21] | HF | Mortality | P | P1 | NS | NR | NR | NR |
| Koehler 2011 [22] | HF | Mortality | NS | NS1 | NS | NR | NR | NR |
| Scherr 2009 [23] | HF | Mortality | NS | NS1 | NS | NR | NR | NR |
| Seto 2012 [24] | HF | BNPh | NS | NR | NR | NR | NR | NR |
| Vuorinen 2014 [25] | HF | Readmissions | NS | NS | NS1 | NR | NR | NR |
| Bobrow 2016 [26] | HTNi | Blood pressure | P | NR | NS | P1 | NR | P |
| Kiselev 2012 [27] | HTN | Blood pressure | P | NR | NR | P1 | NS | NR |
| Logan 2012 [28] | HTN | Blood pressure | P | NR | NR | P1 | NR | NR |
| Morawski 2018 [29] | HTN | Blood pressure | NS | NR | NR | NS1 | NR | P |
| Morikawa 2011 [30] | HTN | Blood pressure | P | NR | NR | P1 | NS | NR |
| Varleta 2017 [31] | HTN | Medication adherence | NS | NR | NR | NS | NR | NS1 |
| Bravo-Escobar 2017 [32] | CRj | Physical fitness | NS | NR | NR | NS | NS | NR |
| Del Rosario 2018 [33] | CR | CR completion rate | P | NR | NR | NS | NS | NR |
| Maddison 2019 [34] | CR | Physical fitness | NS | NR | NR | NR | NR | NR |
| Pandey 2017 [35] | CR | Medication adherence | NS | NR | NR | NR | NR | NS1 |
| Pandey 2017 [35] | CR | Lifestyle adherence | NS | NR | NR | NR | NR | NR |
| Pfaeffli Dale 2015 [36] | CR | Lifestyle adherence | NS | NR | NR | NS | NS | P |
| Piotrowicz 2010 [37] | CR | Functional status | P | NR | NR | NR | NR | NR |
| Varnfield 2014 [38] | CR | CR completion rate | NS | NR | NR | NS | P | NR |
aIHD: ischemic heart disease.
bNS: not significant.
cNR: not reported.
dP: positive.
eP1: positive primary endpoint.
fHF: heart failure.
gNS1: not significant primary endpoint.
hBNP: brain natriuretic peptide.
iHTN: hypertension.
jCR: cardiac rehabilitation.